
CLGN Stock Forecast & Price Target
CLGN Analyst Ratings
Bulls say
CollPlant Biotechnologies Ltd has demonstrated significant advancements in its intellectual property portfolio and strong partnerships, particularly with AbbVie, which has already resulted in $24 million out of a potential $50 million in milestone payments, showcasing commercial viability and confidence in its rhCollagen technology. The recent patent, expiring in 2039, enhances CollPlant's competitive edge in the aesthetics market, further solidifying its long-term growth prospects in regenerative medicine. Additionally, strategic cost reduction initiatives are in place to extend the company's financial runway, positioning it favorably for upcoming human trials and future developments.
Bears say
CollPlant Biotechnologies Ltd operates within a highly specialized market focused on regenerative and aesthetic medicine, primarily relying on its rhCollagen products and BioInk for revenue generation. Despite its innovative technology, the company faces challenges with sales performance in its core markets, particularly in Europe for critical applications like tendinopathy and wound healing, which could undermine its financial stability. Additionally, the reliance on business collaborations for revenue may expose CollPlant to greater volatility and financial risk, further contributing to a negative outlook for its stock.
This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.
CLGN Analyst Forecast & Price Prediction
Start investing in CLGN
Order type
Buy in
Order amount
Est. shares
0 shares